Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 8, 2015

View Archived Issues

GPR37L1 mutation provides insight for novel inherited neurological disorder

Study of sASD markers in Taiwanese population provides new data

Novel approach studied for diagnosis and treatment of DRD

Novel mutation in a deubiquitinating enzyme related to Diamond Blackfan anemia

Phase I study begins for MVA-BN Filo/AdVac preventive Ebola vaccine regimen

Advaxis seeks FDA clearance to study ADXS-HER2 in HER2-expressing solid tumors

Lion Biotechnologies files IND for phase II study of tumor-infiltrating lymphocytes in melanoma

FDA responds to Cesca's IDE application for pivotal critical limb ischemia trial

Kite Pharma to generate CAR T cell therapies against Amgen cancer targets

Kowa divulges insulin secretagogues

Taisho Pharmaceutical reports development of GlyT-1 inhibitors

Seikagaku reports new cathepsin K inhibitors

CSIPI patents novel platinum complexes

Janssen discloses new BACE1/2 inhibitors

European phase III trial of INTERCEPT blood system meets primary endpoint

cCAM Biotherapeutics cleared to begin phase I trial of CM-24 for cancer

SGX-94 reduces pancytopenia in animal model of macrophage activation syndrome

Alkermes reports topline results from phase III study of ALKS-5461 for major depressive disorder

Dignity Sciences anti-fibrotic shows potential in mouse model of NASH

Versartis reports data from ongoing extension study of VRS-317 for growth hormone deficiency

Pfizer's acquires Redvax

KaloBios reports topline data for phase II study of KB001-A

Novartis receives approval in Canada for Fluad Pediatric

Cipher Pharmaceuticals acquires Canadian commercialization rights to ozenoxacin

Gilead Sciences acquires Phenex Pharmaceuticals' FXR liver disease programs

FDA grants SGX-301 fast track designation for cutaneous T-cell lymphoma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 6, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...
KLF15 shows potential as marker, target for cholangiocarcinoma
BioWorld Science
Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...